The FDA’s Office of Prescription Drug Promotion recently reprimanded Sanofi and Viatris for making misleading claims about their products in emails and a television advertisement. FDA issued an ...

A dodgy doctor allegedly injected a Bronx woman before she died with a trendy supposed anti-aging molecule boosted by ...

In the latest pair of Untitled Letters, the FDA took issue with a Viatris TV ad and Sanofi’s promotional emails.

Amjevita and Imraldi, two biosimilar agents for adalimumab (Humira), were just as effective in treating psoriasis as the original drug for both new users and patients who switched from adalimumab to ...

Cosentyx (secukinumab) and Humira (adalimumab) are prescription drugs used to treat similar conditions. Both drugs come as subcutaneous injections, however, Cosentyx may also be given as an ...

SPRINGFIELD, Mass. (WWLP) – Health New England announced Monday that it will shift coverage of the biologic drug Humira to more affordable FDA-approved biosimilars starting next month for members of ...

In May 2025, the FDA approved numerous biosimilars as interchangeable with Stelara ® (ustekinumab) and Humira ® (adalimumab), bringing the total number of Stelara ® interchangeables to four, plus an ...

The Food and Drug Administration has granted an expanded interchangeable designation for Celltrion’s Yuflyma (adalimumab-aaty), now including prefilled syringe (40mg) and autoinjectors (40mg and 80mg) ...

This drug has boxed warnings. These are the most serious warnings from the Food and Drug Administration (FDA). A boxed warning alerts doctors and patients about drug effects that may be dangerous.

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. In a unique legal challenge, the Dutch Pharmaceutical ...

On Friday, AbbVie Inc (NYSE:ABBV) reported an adjusted EPS of $2.46, up 6.5% year over year and beating the consensus of $2.38. The pharmaceutical giant reported sales of $13.34 billion, up 8.4% on a ...

Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...